我們已在上線! 進一步了解
JNCE

Jounce Therapeutics, Inc. Common Stock

已下市

JNCE已於2023年5月3日下市。

 

關於: Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company has developed a suite of integrated technologies that comprise a Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.

員工: 141

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於JNCE的最新新聞文章。

價格圖表採用Lightweight Charts™實作